SCHEMBL23219832

SCHEMBL23219832

CCc1ccnc(OC)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MTNR1A P48039 1/20 0.35
IDO1 P14902 1/20 0.34
TRPA1 O75762 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
SLC13A5 Q86YT5 1/20 0.33
ALOX5AP P20292 2/20 0.33
FEN1 P39748 2/20 0.33
SLC22A12 Q96S37 1/20 0.33
BTK Q06187 1/20 0.33
APLNR P35414 1/20 0.33
CCR1 P32246 1/20 0.32
CCR5 P51681 1/20 0.32
CCR8 P51685 1/20 0.32
GRM2 Q14416 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19330231 0.82 MEN1 (0.39) MTNR1ATRPA1CYP1A2CYP3A4CYP2D6
SCHEMBL19354084 0.82 HPGD (0.34) HPGDSMN1; SMN2MTNR1ATRPA1CYP1A2
SCHEMBL1135178 0.80 LMNA (0.35) HPGDSMN1; SMN2CYP3A4CYP2C9LMNA
SCHEMBL24713403 0.80 IDO1 (0.37) HPGDSMN1; SMN2MTNR1AIDO1SLC13A5
SCHEMBL19330376 0.79 ROCK2 (0.40) HPGDSMN1; SMN2MTNR1AIDO1ACSS2
SCHEMBL24344519 0.78 AURKA (0.38) HPGDSMN1; SMN2MTNR1ASLC13A5BTK
SCHEMBL5942718 0.78 GRM2 (0.38) HPGDSMN1; SMN2MTNR1ASLC13A5GRM2
SCHEMBL24344266 0.78 HPGD (0.46) HPGDSMN1; SMN2MTNR1ASLC13A5BTK
SCHEMBL11967121 0.77 NOS3 (0.33) CYP2D6CYP2C19ALOX5APFEN1
SCHEMBL11970836 0.75 NOS3 (0.35) ALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10975088-B2 Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors INCYTE CORPORATION (US) 2021-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975088-B2 Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors PIK3R5, PIK3CD, PIK3CA HPGD 3901/4885SMN1; SMN2 978/4885MTNR1A 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.